Inclusion criteria were as follows: ability to confirm an individual case patient was greater than 18 years of age; documentation of a loss ofSMARCB1/INI1 expression by immunohistochemistry or genetic studies; and confirmed sarcomatous histologic tumor type. The gene discussed is SMARCB1; the disease is neoplasm.